Revvity, Inc. (RVTY) is a global life sciences and diagnostics company headquartered in Waltham, Massachusetts. Formed as a spin-off from PerkinElmer in 2023, the company supports the healthcare, biotech, and research sectors in several countries. Revvity provides a wide range of solutions, including imaging systems, multi-omics tools, diagnostic technologies, software, and data analytics. 

It operates through two primary divisions: Life Sciences and Diagnostics. With a workforce of over 11,000 employees worldwide, Revvity plays a pivotal role in accelerating scientific discovery, enhancing clinical outcomes, and driving innovation across the healthcare landscape. It has a market capitalization of $10.36 billion. 

Over the past 52 weeks, Revvity’s stock has not performed well, as it has declined by 26.4%. It is also down 20.1% year-to-date (YTD). Therefore, the stock has consistently underperformed in the market during this period. The stock has broadly underperformed the S&P 500 Index ($SPX), which has gained 16.3% and 10.6% over the same periods, respectively. 

Focusing on the healthcare sector, we see that Revvity has been an underperformer in this case as well, as the Health Care Select Sector SPDR Fund (XLV) has been down by 12.4% over the past 52 weeks and has declined marginally YTD. 

On July 28, Revvity reported solid second-quarter results for fiscal 2025. The company reported 4.1% year-over-year (YOY) growth in its revenue to $720.28 million, with growth observed across its Life Sciences and Diagnostics segments. On the other hand, Revvity’s adjusted EPS dropped from $1.22 in Q2 2024 to $1.18 in Q2 2025. However, this figure was higher than the $1.14 adjusted EPS that Wall Street analysts were expecting.

On the other hand, despite the better-than-expected results, Revvity’s stock dropped by 8.3% intraday on July 28. This is because the company’s bottom-line guidance softened. Although Revvity raised its fiscal 2025 topline guidance to a range of $2.84 billion to $2.88 billion, it also cut its adjusted EPS guidance from a range of $4.90 - $5.00 to $4.85 - $4.95. 

For the fiscal year 2025, ending in December 2025, Wall Street analysts expect Revvity’s EPS to decline marginally YOY to $4.87 on a diluted basis, but increase by 11.7% to $5.44 in fiscal 2026. The company has a solid history of surpassing consensus estimates, topping them in all of the trailing four quarters.

Among the 18 Wall Street analysts covering Revvity’s stock, the consensus is a “Moderate Buy.” That’s based on 10 “Strong Buy” ratings, one “Moderate Buy,” and seven “Hold” ratings. The configuration of the ratings has remained stable over the past three months. 

Following its Q2 results, analysts at Raymond James lowered the price target on Revvity’s stock from $120 to $115, while maintaining an “Outperform” rating, citing reimbursement headwinds in China. Citing the same reason, analysts at Stifel also cut the price target from $120 to $110, while keeping their “Hold” rating on the stock. 

Revvity’s mean price target of $115.56 indicates a 29.5% upside over current market prices. The Street-high price target of $135 implies a potential upside of 51.3%.